Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Molnupiravir  COVID-19 treatment studies for Molnupiravir  C19 studies: Molnupiravir  Molnupiravir   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   All Outcomes   Recent:  
0 0.5 1 1.5 2+ Mortality -282% Improvement Relative Risk Mortality (b) -217% Mortality (c) -317% Mortality (d) -311% Recovery 1% Recovery (b) 12% Recovery (c) -1% Recovery time 0% no CI Recovery time (b) 0% no CI Recovery time (c) 0% no CI Viral clearance 12% Viral clearance (b) -2% Viral clearance (c) 21% Viral clearance (d) 8% Viral clearance (e) -48% Viral clearance (f) 21% c19early.org/m Arribas et al. NCT04575584 Molnupiravir RCT LATE Favors molnupiravir Favors control
Randomized Trial of Molnupiravir or Placebo in Patients Hospitalized with Covid-19
Arribas et al., NEJM Evidence, doi:10.1056/EVIDoa2100044, NCT04575584 (history)
Arribas et al., Randomized Trial of Molnupiravir or Placebo in Patients Hospitalized with Covid-19, NEJM Evidence, doi:10.1056/EVIDoa2100044, NCT04575584
Dec 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
RCT 304 hospitalized patients, 218 treated with molnupiravir, showing no significant differences. MOVe-IN MK-4482-001. NCT04575584 (history).
Concerns have been raised that the mutagenic mechanism of action may create dangerous variants or cause cancer [Hadj Hassine, Swanstrom]. See [twitter.com] for analysis of a variant potentially created by molnupiravir.
risk of death, 281.9% higher, RR 3.82, p = 0.31, treatment 11 of 216 (5.1%), control 1 of 75 (1.3%), combined, excluding imputed deaths.
risk of death, 216.9% higher, RR 3.17, p = 0.36, treatment 3 of 71 (4.2%), control 1 of 75 (1.3%), 800mg, excluding imputed death.
risk of death, 316.7% higher, RR 4.17, p = 0.20, treatment 4 of 72 (5.6%), control 1 of 75 (1.3%), 400mg, excluding imputed death.
risk of death, 311.0% higher, RR 4.11, p = 0.21, treatment 4 of 73 (5.5%), control 1 of 75 (1.3%), 200mg.
risk of no recovery, 1.0% lower, RR 0.99, p = 0.96, treatment 72, control 75, inverted to make RR<1 favor treatment, 800mg.
risk of no recovery, 11.5% lower, RR 0.88, p = 0.53, treatment 73, control 75, inverted to make RR<1 favor treatment, 400mg.
risk of no recovery, 1.0% higher, RR 1.01, p = 0.96, treatment 73, control 75, inverted to make RR<1 favor treatment, 200mg.
recovery time, no change, relative time 1.00, treatment 72, control 75, 800mg.
recovery time, no change, relative time 1.00, treatment 73, control 75, 400mg.
recovery time, no change, relative time 1.00, treatment 73, control 75, 200mg.
risk of no viral clearance, 11.8% lower, RR 0.88, p = 0.57, treatment 26 of 52 (50.0%), control 34 of 60 (56.7%), NNT 15, 800mg, Table S16, day 15 mid-recovery.
risk of no viral clearance, 2.4% higher, RR 1.02, p = 1.00, treatment 29 of 50 (58.0%), control 34 of 60 (56.7%), 400mg, Table S16, day 15 mid-recovery.
risk of no viral clearance, 20.6% lower, RR 0.79, p = 0.27, treatment 27 of 60 (45.0%), control 34 of 60 (56.7%), NNT 8.6, 200mg, Table S16, day 15 mid-recovery.
risk of no viral clearance, 8.3% lower, RR 0.92, p = 1.00, treatment 9 of 53 (17.0%), control 10 of 54 (18.5%), NNT 65, 800mg, Table S16, day 29.
risk of no viral clearance, 48.2% higher, RR 1.48, p = 0.35, treatment 14 of 51 (27.5%), control 10 of 54 (18.5%), 400mg, Table S16, day 29.
risk of no viral clearance, 21.5% lower, RR 0.79, p = 0.61, treatment 8 of 55 (14.5%), control 10 of 54 (18.5%), NNT 25, 200mg, Table S16, day 29.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Arribas et al., 16 Dec 2021, Double Blind Randomized Controlled Trial, multiple countries, peer-reviewed, 21 authors, average treatment delay 7.1 days, trial NCT04575584 (history).
All Studies   All Outcomes   Submit Updates or Corrections
This PaperMolnupiravirAll
Abstract: Published December 16, 2021 DOI: 10.1056/EVIDoa2100044 ORIGINAL ARTICLE Randomized Trial of Molnupiravir or Placebo in Patients Hospitalized with Covid-19 Jose R. Arribas, M.D.1, Sanjay Bhagani, M.D.2, Suzana M. Lobo, M.D., Ph.D.3, Ilsiyar Khaertynova, M.D.4, Lourdes Mateu, M.D., Ph.D.5, Roman Fishchuk, M.D.6, William Y. Park, M.D.7, Khetam Hussein, M.D.8, Sei Won Kim, M.D.9, Jade Ghosn, M.D.10,11, Michelle L. Brown, B.S.12, Ying Zhang, Ph.D.12, Wei Gao, Ph.D.12, Christopher Assaid, Ph.D.12, Jay A. Grobler, Ph.D.12, Julie Strizki, Ph.D.12, Mary Vesnesky, B.A.12, Amanda Paschke, M.D.12, Joan R. Butterton, M.D.12, Carisa De Anda, Pharm.D.12, on behalf of the MOVe-IN study group Abstract BACKGROUND Molnupiravir is an oral prodrug of b-D-N4-hydroxycytidine, active against SARS-CoV-2 in vitro and in animal models. We report data from the phase 2 component of MOVe-IN, a clinical trial evaluating molnupiravir in patients hospitalized with Covid-19. METHODS We conducted a randomized, placebo-controlled, double-blind phase 2/3 trial in patients 18 years old and older requiring in-hospital treatment for laboratoryconfirmed Covid-19 with symptom onset 10 or fewer days before randomization. Participants were randomly assigned to placebo or molnupiravir 200 mg, 400 mg, or 800 mg (1:1:1:1 ratio), twice daily for 5 days. Primary end points were safety and sustained recovery (participant alive and either not hospitalized or medically ready for discharge) through day 29. RESULTS Of 304 randomly assigned participants, 218 received at least one dose of molnupiravir and 75 of placebo. At baseline, 74.0% had at least one risk factor for severe Covid-19. Adverse events were reported in 121 of 218 (55.5%) molnupiravir-treated and 46 of 75 (61.3%) placebo-treated participants, with no apparent dose effect on adverse event rates and no evidence of hematologic toxicity based on prespecified adverse events. Of 16 confirmed deaths, most were in participants with severe Covid-19 (75.0%), with underlying comorbidities (87.5%), older than 60 years of age (81.3%), and/or symptom duration longer than 5 days (75.0%) at randomization. Median time to sustained recovery was 9 days in all groups, with similar day 29 recovery rates ranging from 81.5% to 85.2%. CONCLUSIONS In this phase 2 trial of patients hospitalized with Covid-19, a 5-day course of molnupiravir up to 800 mg twice daily was not associated with dose-limiting For personal use only. No other uses without permission. Copyright © 2021 Massachusetts Medical Society. The author affiliations are listed at the end of the article. Dr. De Anda can be contacted at carisa.de.anda@merck.com or at Merck & Co. Inc., 309 N Sumneytown Pike, North Wales, PA 19454. side effects or adverse events, but did not demonstrate clinical benefit. (Funded by Merck Sharp & Dohme; ClinicalTrials.gov NCT04575584.)
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit